Evaluation and Prediction of Anti-Malarial Activity by UbiquinolCytochrome-C Reductase Inhibition of Active Constituents of Ipomoea Carnea with Marketed Drug Atovaquone

Abstract

Background: In 2017, 219 million cases of malaria across worldwide were estimated by World Health Organization and there were 435 thousands deaths were expected. African countries have the most number of cases and deaths due to malaria (~90%). Atovaquone is marketed drug used in the treatment of malaria. It shows inhibition of the Ubiquinol-cytochrome-c reductase activity in intra erythrocytes parasitic ETC pathway. Bush Morning Glory also known as Ipomoea carnea is a herbal medicinal plant which is used from ancient times to treat various diseases. There are various reported pharmacological activities of Ipomea carnea against various disorders. In this study using in silico drug discovery tools, the anti malarial potential is evaluated and compared with Atovaquone. Method: Anti malarial activity of active chemical constituents of Ipomoea carnea was studied with the help of In-silico passonline predication tool and molecular Protein-Ligand docking tool “swissdock”. Result: The data of anti-malarial activity and Molecular Protein-Ligand docking of chemical constituents of Ipomoea carnea was compared with Atovaquone data. It was observed that chemical constituents of Ipomoea carnea have more Pa value than Atovaquone for anti malarial activity. It was also observed that Stearic acid, Linoleic acid and Hexadecanoic acid binds to Ubiquinol-cytochrome-c reductase with high affinity and low binding affinity energy. Conclusion: It was also observed that Stearic acid, Linoleic acid and Hexadecanoic acid binds to Ubiquinol-cytochrome-c reductase with high affinity and low binding affinity energy. Therefore, these compounds of Ipomoea carnea have potential anti-malarial activity